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 Abstract 
 Background: Manufacturers and laboratories might 
benefit from using a modern integrated tool for quality 
management/assurance. The tool should not be con-
founded by commutability issues and focus on the intrin-
sic analytical quality and comparability of assays as 
performed in routine laboratories. In addition, it should 
enable monitoring of long-term stability of performance, 
with the possibility to quasi  “ real-time ” remedial action. 
Therefore, we developed the  “ Empower ” project. 
 Methods: The project comprises four pillars: (i) master 
comparisons with panels of frozen single-donation 
samples, (ii) monitoring of patient percentiles and (iii) 
internal quality control data, and (iv) conceptual and sta-
tistical education about analytical quality. In the pillars 
described here (i and ii), state-of-the-art as well as biologi-
cally derived specifications are used. 
 Results: In the 2014 master comparisons survey, 125 labo-
ratories forming 8 peer groups participated. It showed 
not only good intrinsic analytical quality of assays but 
also assay biases/non-comparability. Although labora-
tory performance was mostly satisfactory, sometimes 
huge between-laboratory differences were observed. In 
patient percentile monitoring, currently, 100 laboratories 
participate with 182 devices. Particularly, laboratories 
with a high daily throughput and low patient popula-
tion variation show a stable moving median in time with 
good between-instrument concordance. Shifts/drifts due 
to lot changes are sometimes revealed. There is evidence 
that outpatient medians mirror the calibration set-points 
shown in the master comparisons. 
 Conclusions: The Empower project gives manufacturers 
and laboratories a realistic view on assay quality/com-
parability as well as stability of performance and/or the 
reasons for increased variation. Therefore, it is a modern 
tool for quality management/assurance toward improved 
patient care. 
 Keywords:  analytical/population variation;  bias;  drift; 
 median;  moving median;  outpatients;  quality indicators; 
 shift. 
 Introduction 
 Manufacturers and laboratories have common inter-
est in precise, unbiased, and stable in vitro diagnostic 
assays enabling optimal patient care. Although they 
both monitor the above test attributes, they have dif-
ferent objectives and access to existing data, which are 
facts that might hamper the dialogue between them. For 
example, manufacturers are mainly interested in the 
global performance of their assays ( = peer performance), 
whereas laboratories rather focus on their own perfor-
mance. However, for troubleshooting purposes, peer 
performance is also of interest to laboratories. Manu-
facturers monitor laboratories by an online link with 
their systems, whereas laboratories have easy access 
to their own data. The data sources can be bridged by 
independent third-party programs for peer group-based 
combined internal quality control (IQC)/external quality 
assessment (EQA). However, this approach has limita-
tions. Commutability issues of the used materials make 
that peer group assessment cannot give information on 
trueness of performance. Additionally, it may cause that 
variations in patient data (e.g., trends and shifts due to 
reagent lot changes) are not well reflected  [1 – 3] . Besides, 
continuous monitoring of the results is rather the excep-
tion, and even if done, the data are usually not accessible 
in real time. In addition, the external program providers 
mostly do not critically review or publish the data, but 
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leave the interpretation to the participating laboratories. 
This practice is of course driven by the commercial sur-
rounding in which they operate, which hampers them to 
disclose performance data of individual diagnostic man-
ufacturers. In contrast, independent national or regional 
EQA schemes theoretically are in the position to openly 
demonstrate the performance of commercial test systems. 
However, this requires that sufficient laboratories partici-
pate, so that the peer groups can be well defined. This 
is for most of the schemes not possible, therefore, they 
rather restrict to assessing the competence of laboratories 
 [2, 3] . This is in turn limited by the fact that EQA schemes 
seldom work with fully commutable materials, conduct 
surveys at low frequency and report retrospectively. From 
this perspective, it would be desirable to implement an 
independently operated  “ online ” tool that enables to 
monitor comparability and stability between peer groups 
and laboratories without being confounded by non-com-
mutability issues because it uses real patient samples. To 
maximize the utility of the tool, the information should 
be shared between participants and manufacturers but 
within confidentiality constraints. This means that an 
individual evaluation report should only be available to 
the laboratory to which it applies. The tool could in the 
same time serve to empower laboratories for the future 
tasks they face, among others, providing input for the 
development and implementation of global health-care 
policies. 
 In response to these needs, we initiated the so-called 
Empower project. It is intended to establish a bottom-up 
cooperation between laboratories and manufacturers, so 
that they can pursue the common objective of assessing 
and improving test comparability and stability, whereby 
we see our role as independent third party mediator. It 
is our strong belief that such a transparent cooperation 
will be of benefit to all stakeholders involved in labo-
ratory medicine. The project stands on four pillars: (i) 
master comparisons with fresh-frozen single-donation 
serum samples; (ii) monitoring of patient percentiles 
and (iii) IQC, both across laboratories and manufactur-
ers; (iv) conceptual and statistical education about ana-
lytical quality in the medical laboratory (e.g., analytical 
performance specifications) and elaboration of statisti-
cally sound and  “ actionable ” experiments for analytical 
quality management and assurance. Laboratories are 
free to participate in all pillars of our project or to select 
the most appropriate one(s) for their purpose. Here, we 
report on the status of the project with respect to the 
master comparisons and patient percentile monitoring 
and share the first observations on test comparability 
and stability of performance. 
 Materials and methods 
 Master comparisons 
 As previously described, we conduct the master comparison surveys 
for diagnostic assays with panels of 20 fresh-frozen, single-donation, 
commutable serum samples (each available in a volume of approx. 
180 mL)  [4 – 6] . The samples are prepared using the Clinical and 
Laboratory Standards Institute C37-A protocol, however, without 
pooling and fi ltration and are dispatched on dry ice  [7] . Participa-
tion is made conditional of the use of a homogeneous test system, 
i.e., instrument, reagent, and calibrator from the same manufacturer. 
The number and selection of laboratories is adapted to obtain peer 
groups representing the main manufacturers/diagnostic test systems 
(approx. 20 laboratories per manufacturer/system). Participation 
also includes the in-house laboratories of the respective manufac-
turers. For each survey, we select eight diff erent analytes from the 
clinical chemistry test menu of modern platforms (for the analytes 
covered up to now, see  Table 1 ). The participants are requested to do 
the measurement in singlet under within-run conditions. The quality 
of assays and laboratories is assessed from four quality indicators at 
the peer group and  “ reference ” level. The latter uses either the all 
manufacturer trimmed mean (AMTM) or reference method values 
as target: (i) the standard error of the estimate (% S y/x ) from linear 
regression analysis: if data are compared with the peer group mean, 
the S y/x is a measure for within-run imprecision; if compared with the 
reference target, it refl ects the combined imprecision (both random 
and sample related eff ects); (ii) bias (%) at the mean concentration 
and the range limits (low and high concentration end); (iii) total error 
(%); (iv) the number of results observed outside the total error limits. 
These estimates are tested against a hierarchy of decision limits, i.e., 
limits that account for state-of-the-art performance, but also limits 
derived from biological variation data  [9] . 
 Patient percentile monitoring 
 We monitor the daily medians of the results for 20 commonly meas-
ured analytes in serum or plasma. All types and sizes of laboratories 
can participate. The laboratories calculate instrument-specifi c daily 
medians from outpatient results and send the data by e-mail to our 
database. Several vendors of laboratory information systems off er 
cost-free solutions for automatic calculation and electronic transfer. 
Alternative solutions are extraction of weekly/monthly data from 
the system and shipment in batch. Formats readable in our data-
base are an e-mail-embedded table, Excel fi les, and text fi les (Sup-
plementary Material, Table 1, that accompanies the article  http://
www.degruyter.com/view/j/cclm.2015.53.issue-8/cclm-2014-0959/
cclm-2014-0959.xml?format = INT ). Note that we do the mapping of 
the laboratories ’ mnemonics for the diff erent analytes and units for 
expression of the medians. Via a user interface with authentication 
(access by user name and password) for secured authorization, the 
participating laboratory can plot for each analyte the course of the 
moving median. If a laboratory reports medians for diff erent instru-
ments, the moving medians (instrument-specifi c colored) are shown 
in the same plot. For interpretation, preliminary desirable limits for 
mid- to long-term bias are included. These are guided by biological 
variation and state-of-the-art performance (Supplementary Material, 
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 Table 1   Overview of the analytes covered in the Empower project. 
Analytes covered in the master comparisons and patient percentile monitoring 
Alanine aminotransferase a Glucose b 
Albumin c Lactate dehydrogenase a 
Alkaline phosphatase a Magnesium c 
Aspartate aminotransferase a Phosphate b 
Calcium c Potassium a 
Chloride a Sodium a 
Total cholesterol b Total protein c 
Creatinine b Total triglycerides b 
 γ -Glutamyl transferase a Uric acid (urate) b 
 Analytes only covered in the master comparisons  Analytes only covered in the patient percentile monitoring 
HDL-cholesterol b C-reactive protein
LDL-cholesterol b Total bilirubin 
 Analytes covered in references  a [8] ,  b [6] , and  c [5] , respectively. 
Table 2). The user application allows selection of (i) the number of 
consecutive medians (n = 5, 8, 16) used for calculation of the moving 
median, (ii) time window, and (iii) exclusion of data from weekends. 
Each plot also shows the long-term median of the concerned indi-
vidual laboratory as well as the peer group or all devices median 
(freely to select). Additional numerical information is provided on 
the long-term imprecision (the so-called robust CV, %) and the bias 
calculated in comparison to the peer group or all devices target as 
well as a  “ desirable ” target. Currently, we use the medians of the 
reference intervals determined in the trueness-based  “ Nordic Refer-
ence Interval Project (NORIP) ” as preliminary reference source for 
that target  [10] . The user can download and print the plots. He has 
also access to his own entries in the database with the possibility 
to fi lter/sort according to analyte/date. This facilitates tracing back 
on which date graphical aberrant observations started. The graphi-
cal user interface can be accessed at  https://www.thepercentiler.be/ 
(to see the demo version, log in with  “ demolab ” as username and 
 “ demo1234 ” as password). A screenshot is given in the Supplemen-
tary Material,  Figure 1 . 
 Results 
 Status of the project 
 Results of the master comparison surveys conducted up 
to now are described elsewhere  [4 – 6, 8] . The online Sup-
plemental  Figure 2 shows that in the most recent survey 
(2014), a total of 125 laboratories from 21 different coun-
tries (15 in Europe and Australia, Canada, Malaysia, South 
Korea, Singapore, and the USA) participated. The five 
main manufacturers also joined with their in-house labo-
ratories (Abbott, Beckman, Ortho, Roche, and Siemens). 
In the patient percentile monitoring part, currently, 100 
laboratories from 15 different countries (11 in Europe and 
Australia, India, Russia, and the USA) are participating 
with a total of 182 devices (Supplementary Material, 
 Figure 2 ). Most of the test systems involved in the 2014 
master comparison survey are also represented in percen-
tile monitoring (Supplementary Material, Table 3).  Table 1 
shows that most analytes covered in the master compari-
sons (20 until now) are also addressed in patient percen-
tile monitoring. 
 Test performance, comparability across 
 manufacturers, and laboratory performance 
 As described elsewhere in detail, the design of the 
master comparisons with 20 single-donation commutable 
samples allows to assess different performance attributes 
of the examined assays and also individual laboratory 
performance  [4 – 6] . Apart from some exceptions, assay 
peer group assessment showed a good intrinsic analytical 
quality in terms of within-run and combined imprecision 
and total error. It also demonstrated sufficient robustness 
for satisfactory performance in a daily laboratory context. 
However, there was room for improvement at higher and 
lower concentrations. Assessment at the reference level 
showed for several analytes good comparability between 
manufacturers/assays, e.g., for total protein, cholesterol, 
glucose, phosphate, uric acid  [5, 6] , whereas for others, 
considerable calibration differences were obvious, e.g., 
for albumin  [5] . Particularly striking in this regard were 
the biases against the targets for enzymes set by the IFCC 
reference methods  [8, 11 – 15] . Also, long-term assay drift/
uncorrected biases for a single manufacturer were some-
times uncovered, e.g., magnesium, creatinine, low density 
lipoprotein (LDL) cholesterol, phosphate, uric acid, and 
chloride in  [5, 6, 8] . Assessment against the reference 
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method or AMTM showed for most assays and analytes 
sufficient analytical specificity, but for others, vulnerabil-
ity to sample-related effects, e.g., high density lipoprotein 
(HDL) and LDL cholesterol in  [6] . The bias limits used for 
assessment demonstrated that for certain analytes, the 
state of the art is such that most assays, apart from some, 
can meet the desirable biological variation bias specifi-
cations (e.g., for total protein, phosphate, triglycerides, 
uric acid, alkaline phosphatase, potassium  [5, 6, 8] ). For 
some biologically more tightly regulated analytes, the 
biologically inferred limits are not feasible, e.g., glucose, 
cholesterol, chloride  [6] , or would require improvement 
of lot-to-lot consistency, e.g., calcium  [5] . In contrast, 
sodium assays showed exceptionally well performing, 
almost within the tight biological bias limit  [8] . Assess-
ment of the laboratory performance strikingly showed that 
sometimes large between-laboratory differences ( > 30%) 
occurred for all analytes  [6, 8] . These discrepancies could 
partly be ascribed to the biases in the used assays but also 
likely point to severe laboratory effects on performance of 
assays in daily practice. 
 Similar observations were made from the patient per-
centile monitoring data. For example, the median values 
matched the aforementioned calibration differences 
revealed for  γ -glutamyl transferase and chloride in the 
2014 master comparison survey ( Figure 1 )  [8] . Indeed the 
 γ -glutamyl transferase moving median values ranged from 
approximately 20 to approximately 32 U/L, those for chlo-
ride from approximately 101 to approximately 105 mmol/L. 
 Stability of laboratory/test performance 
 First, results from patient percentile monitoring show 
that laboratories with high daily throughput and/or low 
variation in patient population typically perform with low 
variation and mostly good concordance between the dif-
ferent instruments (Supplementary Material,  Figure 3 A). 
Other laboratories have a higher long-term variation in 
performance. If this is due to a lower throughput or higher 
population variation (typical for laboratories operating 
in a medium-sized hospital), the variation can partly 
be reduced by selecting a higher n for calculation of the 
moving median (Supplementary Material,  Figure 3 B and 
C). Other observations are about drifts or shifts, transient 
to long-term bias, e.g., between different instruments 
used in a laboratory, of one particular instrument com-
pared with the others, or of the laboratory compared with 
its peer. Interestingly, shifts or drifts sometimes apply for 
several laboratories belonging to the same peer, which 
confirms that they are caused by a major manufacturer 
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 Figure 1   Illustration of the match between the peer group means 
(red rectangles) in the 2014 survey of the master comparisons and 
the median values (blue rectangles) in patient percentile monitoring 
for  γ -glutamyl transferase (GGT) and chloride. 
event, e.g., a reagent or calibrator lot change ( Figure 2 A 
and B). In other cases, laboratories can relate the observed 
instability to a calibration event (example shown in  Figure 
2 C). Although certain observations can rather easily be 
explained, longer observation times and more solid peer 
groups are needed for a systematic investigation of the 
root causes. 
 Discussion 
 The Empower project is an integrated quality assurance 
tool for laboratories and manufacturers. Its unique design 
based on real patient results allows to assess/demonstrate 
quality aspects without being confounded by commut-
ability issues  [16, 17] . It facilitates remediating actions 
because it reveals major bias components/sources, such 
as the manufacturer (assay), laboratory, instrument, the 
reagent/calibrator lot, and recalibration by the laboratory 
itself ( Figure 3 ). 
 The focus of the master comparisons, which are con-
ducted across assays and laboratories, is on how well 
the intrinsic analytical quality of assays on release by 
the respective manufacturers is reproduced by the end 
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users under  “ field ” conditions all over the world. Target 
setting is based on reference method measurements or 
the AMTM. These targets allow to assess either the real 
traceability (standardization status) or the comparabil-
ity between assays and laboratories. The information on 
traceability is of utmost use for the discipline of clinical 
chemistry to investigate the extent of implementation of 
standardization efforts. Note in this regard the striking 
example of the bias observed for enzyme assays. For the 
individual laboratory, it is first-hand information that can 
help in decisions on the acquisition of new instruments. 
As such, the master comparisons provide the participat-
ing laboratories with a reliable calibration fix-point of 
their own performance within the peer group and of the 
latter compared with other peers. Naturally, this is only a 
point estimate in time that should continuously be moni-
tored. This is where patient percentile (and IQC) monitor-
ing comes into play. Indeed, the stability of the peer group 
calibration fix-points can be appreciated from concordant 
medians from outpatient results ( Figure 1 ). In addition, 
laboratories can use their medians as a tool to monitor the 
mid- to long-term stability of their own calibration status, 
again in comparison to their peer, and/or to uncover 
shifts/drifts and the sources thereof  [18] . Of course, this 
requires that the moving medians in time truly reflect the 
analytical variation, without being confounded by other 
sources of variation. In a pilot study, we showed that by 
22
21
20
19
18
17
16
15
Jan '13 May '13 Sep '13 Jan '14
ALT
Chloride
ALT
Va
lu
e,
 
U/
L
Va
lu
e,
 
m
m
o
l/L
Va
lu
e,
 
U/
L
A
103
102.5
102
101.5
101
100.5
100
B
37.5
35
32.5
30
27.5
25
C
May '14
Jan '14
Sep '13 Oct '13 Nov '13 Dec '13 Jan '14 Feb '14 Mar '14
Feb '14 Mar '14 Apr '14 May '14
 Figure 2   Significant test instability for alanine aminotransferase (ALT) 
and chloride due to a confirmed reagent lot change (A), a calibrator lot 
change (B), and a laboratory calibration event (C). 
 In (A) and (B), it is illustrated how lot changes can disturb the stable 
performance. The long broken gray line represents the median 
calculated from all daily medians provided by the laboratory to 
which the graph applies. In (C), the moving median for one of the 
instruments (red colored full line) started to drift around the 20th of 
December 2013, and on 12th February 2014, both instruments (also 
the blue one) were recalibrated by the laboratory, which caused 
in both a shift. The shifts moved the medians outside the stabil-
ity zone (shaded area between short broken gray lines). The black 
short broken line represents the peer group moving medians in (A), 
(B), and (C). 
Master
comparisons
Percentile
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Device type
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Device type
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 Figure 3   Assessment (and control) of bias components/sources. 
 Components in black can be assessed by the above standing pillar, 
those in orange cannot; those in red probably also can in high-
throughput laboratories that mainly work with general practitioners 
(samples almost exclusively from outpatients). 
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working with medians from outpatients and omitting 
medians from weekends and holidays (days with lower 
throughput and/or altered ratios of inpatients to outpa-
tients), the effect of patient population variability can be 
suppressed. We inferred this from a congruent course in 
time of the moving medians and mean of daily IQC data 
 [18] . Meanwhile, it is our experience that in high-through-
put laboratories mainly serving outpatients, the moving 
medians can be calculated from a low number of daily 
medians (n = 5). This is the ideal number for detection 
of analytical instabilities (shifts, drifts). In contrast, for 
laboratories in a hospital context, a higher n is required 
to partly compensate for the effect of a more variable 
patient population and lower throughput. We offer in the 
user interface n = 8 or 16, but the latter is the limit needed 
to prevent too much smoothing and loss of resolution. 
Another asset of the percentile monitoring design is that 
it shows the instrument-specific stability in one plot. This 
allows the laboratories to monitor the interchangeability 
of results among different instruments and/or detect the 
occurrence of instrument-specific special events. 
 Notwithstanding the above potential of the percentile 
monitoring tool, we recommend the users to do the inter-
pretation with caution. Indeed, certain influential factors 
may explain aberrant or more variable medians. We 
learned, for example, that in hospital laboratories, dialy-
sis or oncology patients are often registered as outpatient 
and that their samples are preferentially measured on one 
instrument. Note, however, that by closely working with 
our participants, we can share our experience to enable 
more critical interpretation. We also recommend sample 
exchange between partner laboratories belonging to the 
same peer group and preferably participating in patient 
percentile monitoring because this may be very helpful to 
exclude or confirm observed laboratory biases. 
 We want to emphasize that monitoring of patient 
medians is not a substitute for daily IQC. We advocate it as 
a complementary observation tool from patient data that 
can cover much longer observation times. 
 A fundamental question in all parts of the Empower 
project is whether the observed differences in quality of 
performance or instability are to be considered significant. 
This points to the importance of performance specifica-
tions for meaningful conclusions  [19 – 22] . In the absence 
of a consensus on this topic, we use preliminary limits 
that are guided by biological variation  [9] , and also by 
state-of-the-art performance (for the master comparisons, 
we refer to  [6] ; for the patient percentile monitoring, see 
online Supplemental Table 2). This means that for tightly 
regulated analytes, we expand the limits based on biologi-
cal variation to account for the current quality offered by 
manufacturers. Note that for patient percentile monitor-
ing, we express the limits for allowable bias in absolute 
terms (tailored to the used SI units). The reason is that this 
allows us to show them in the user interface as so-called 
stability limits that should not be exceeded by longer than 
1 week. See, for example, the shaded zone between 17 
and 19 U/L (median ± 2 U/L) in  Figure 2 A for alanine ami-
notransferase. Interestingly, we found the patient percen-
tile monitoring an excellent tool to test how realistic our 
quality goals are, e.g., the stability limit of 1 mmol/L for 
sodium  [23] . For other analytes with very high biologi-
cal variation, such as C-reactive protein, we set a general 
upper limit of approximately 10%. 
 Another important question is which targets to use. 
For the master comparisons part, this is discussed else-
where  [6] . In the percentile monitoring part, we compare 
the medians in first instance not only with the peer group 
medians but also with a reference median. We use the 
median from the NORIP reference intervals, which is, to 
the best of our knowledge, the only source that claims to 
be  “ trueness-based ”  [10] . The reliability is high for ana-
lytes such as sodium and calcium, but the information 
for some enzymes has to be interpreted critically. There 
have been changes in the IFCC-recommended methods, 
and it is known that these are either not carefully or uni-
formly adopted by manufacturers. Therefore, we still 
consider NORIP as a preliminary reference source and 
will follow up, e.g., by cross-comparison with the refer-
ence interval information from manufacturers and new 
projects. 
 Of course, the utility of our project has to be improved 
on a continuous basis. For example, we aim at a platform 
that stimulates the dialogue on a basis of trust between 
the participant laboratories and manufacturers. We work 
on this by establishing close contacts with both parties. 
We also plan to develop a new tool that investigates the 
effect of analytical (in)stability on a surrogate medical 
outcome, such as the frequency of  “ flagged results ”  [18] . 
Together with realistic quality goals that result in mean-
ingful conclusions, this tool might be an excellent basis 
to strengthen the physician/laboratory interface by 
more transparent communication on performance. The 
Empower database potentially can become a source for 
 “ big data mining ” with utility for studies that relate the 
outcome of therapeutic strategies to median values in 
patient cohorts (e.g., the Dialysis Outcomes and Practice 
Patterns Study)  [24] . From the perspective that the pro-
ject ’ s general emphasis is on interchangeability of labora-
tory results, it can potentially also contribute to modern 
clinical needs such as the definition of common reference 
intervals or clinical decision limits, implementation of 
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electronic health records, and development of evidence-
based clinical practice guidelines for application of con-
sistent standards of medical care. 
 Conclusions 
 The Empower project provides evidence on the intrinsic 
quality of assays and how this quality is sustained under 
field conditions. It also demonstrates how well assays 
and laboratories compare and how stable they perform. 
In addition, it enables to uncover all major bias compo-
nents/sources. The major asset of the project is that it 
works with data generated from real patient samples and 
can be linked to observations in daily IQC practice. From 
this perspective, we believe it is a new integrated tool for 
modern quality management of benefit to all stakehold-
ers with interest in reliable laboratory data. It can help the 
discipline of clinical chemistry to derive realistic quality 
specifications and can strengthen the laboratory/manu-
facturer dialogue and laboratory/physician interface. 
Ultimately, if the evidence provided by the project is trans-
lated into action by laboratories and manufacturers, it can 
contribute to a yet to be established translational labora-
tory medicine and better patient care. 
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